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Abstract
Background: Chronic kidney disease (CKD) and end-stage-kidney disease (ESKD) continue to be under-diagnosed
and a major burden for Aboriginal communities in central Australia. The aim of this study was to examine the risk
of poor clinical outcomes associated with elevated albumin-to-creatinine ratio (ACR) among Aboriginal people in
central Australia.
Methods: Cox proportional hazards models were used to estimate the risk of end stage kidney disease (ESKD),
dialysis, CVD (cardiovascular disease) and mortality associated with participants’ baseline albuminuria reading from a
10-year cohort study of Aboriginal people (n = 623) from three communities in central Australia. Predictors of
progression of albuminuria were also examined in the context of the Kidney Health Australia (KHA) Risk Matrix.
Results: A baseline ACR level of ≥3.5 mg/mmol was associated with an almost 10-fold increased risk of ESKD
(95%CI 2.07-43.8) and a 15-fold risk of dialysis (95%CI 1.89-121). Albuminuria ≥3.5 mg/mmol was also associated
with a borderline 63 % increased risk of CVD (95%CI 0.98-2.71). No significant association was observed with
mortality from all-causes or chronic disease. Diabetes and a waist-to-hip ratio ≥0.90 independently predicted a
two-fold increased risk of a progression to higher ACR levels.
Conclusions: A single measure of moderately increased albuminuria was a strong predictor of renal failure in this
population. A single spot urine ACR analysis in conjunction with the KHA Risk Matrix may be a useful and efficient
strategy to screen for risk of CKD and progression to dialysis in remote communities. A focus on individuals with
diabetes and/or central obesity for strategies to avoid increases in albuminuria may also prevent future CKD and
CVD complications.
Keywords: Aboriginal people, Albuminuria, Albumin creatinine ratio, Risk, Cohort study, End stage renal disease,
Rural and remote health
Background
Recent social history has resulted in chronic kidney dis-
ease (CKD) and end-stage-kidney disease (ESKD) among
Aboriginal and Torres Strait Islander communities oc-
curring at disproportionately high rates [1, 2] and has
been described as an ‘epidemic’ [3]. Risk factors for CKD
are likely to be established prior to birth and include
environmental and economic determinants arising from
invasion and colonisation, and the resulting prevalence
of low birthweight/nephron endowment, persistent in-
fections, obesity, hypertension, type-2 diabetes, and the
“Westernisation” of diets [4, 5]. These antecedent factors
also coincide with the increased risk of other chronic
diseases such as cardiovascular disease (CVD) and as
these multiple factors accumulate across a person’s life
course, a very high risk for chronic disease is created [2,
5]. Furthermore, Aboriginal people have a multiplicity of
barriers, including geographical barriers, in receiving ef-
ficacious treatment for ESKD [6]; are more likely to be
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referred late for care; there is often a need for relocation
to urban centres; and Aboriginal people are less likely
than non-Aboriginal people to receive a kidney trans-
plant [1, 6, 7]. As a result of CKD, communities experi-
ence strong negative impacts from the loss of
community members who must relocate for treatment,
premature death and increased health care costs for pri-
mary health care services [6, 8, 9]. Early symptoms of
CKD are often silent [8, 10, 11] and little is known about
the burden of early CKD for Aboriginal people [1] or of
indicators of who progresses to ESKD. The prevalence
of preventable chronic diseases, including CKD, have
been found to be significantly underestimated, particu-
larly in remote Australian communities, thus highlight-
ing gaps in diagnosis and treatment of CKD [12].
Albuminuria and glomerular function are well-known
markers for kidney decline and function [11] however
research into the association of albuminuria and its pre-
dictive value for ESKD among Aboriginal and Torres
Strait Islander populations in Australia is limited [2].
Kidney Health Australia (KHA) has developed a risk
matrix to guide clinical CKD management, such as fu-
ture checks and recommended clinical actions, accord-
ing to stage of albuminuria and glomerular function [11]
based on prospective population health outcome data
[13]. A CKD diagnosis involves either two abnormal esti-
mated glomerular filtration rate (eGFR) measurements
at least three months apart or two abnormal albumin/
creatinine ratio (ACR mg/mmol) measurements at least
three months apart [11, 14, 15]. The KHA Risk Matrix is
incorporated in the Australian recommendations for
CKD diagnosis and management and has also been inte-
grated in the latest edition of the Central Australian
Rural Practitioners Association (CARPA) Standard
Treatment guidelines [15]. However, a non-invasive and
simpler method applicable to the remote setting for
screening to identify future CKD risk is required. The
single spot urine ACR measurement is included in the
Medicare Adult Health Check for Aboriginal and Torres
Strait Islander adults [11] and could be a candidate
screening tool for assessing future ESKD risk. It is a sim-
ple and cost effective method accepted among Aborigi-
nal Health Workers and Aboriginal health service users
in remote areas [9] and is amenable to point of care test-
ing [16]. Such a screening tool could trigger preventive
strategies for CKD progression including use of appro-
priate pharmacological and non-pharmacological inter-
ventions [4, 15] before a clinical diagnosis of CKD.
Using data from a longitudinal cohort study in central
Australia, this study aimed to document the outcomes
of renal disease, CVD and mortality according to a sin-
gle baseline assessment of albuminuria. It aimed to
evaluate the applicability of using a single ACR measure-
ment as a screening tool for identifying CKD risk in the
primary health care setting in central Australia. Further,
given that chronic kidney disease (CKD) and end-stage-
kidney disease (ESKD) continue to be under-diagnosed
and a major public health burden for Aboriginal in re-
mote communities, this study aimed to identify possible
candidates for further screening and CKD prevention
strategies by following the progression of participants to
worsening albuminuria according the risk categories de-
scribed in the KHA Risk Matrix (green (normal risk),
yellow (mildly increased risk) and red (very high in-
creased risk)) [11]. As a result, this study aimed to have
real and practical screening implications for primary
health care clinics in remote settings in identifying Abo-
riginal individuals at elevated risk of CKD and progres-
sion to dialysis.
Methods
The central Australian CVD cohort study is longitudinal
retrospective cohort study designed to assess CVD risk
factors in three remote central Australian communities
[17–19]. The details of recruitment, measurement of
baseline variables and biological sample collection in
1995 have been previously reported [17–19]. Participa-
tion was voluntary and response rates were 68-85 % of
the eligible adult population and 738 persons form the
current cohort. As culturally appropriate and for logis-
tical reasons, ACR in early morning urine samples were
used as a marker of albumin excretion rate rather than
24 h specimens [18]. Urinary albumin concentration was
measured using immunonephelometer (Kallestadt
QM300 or Beckman 360 Array nephelometers; interas-
say coffecient of variance [CV] 3-5 %). Urinary creatin-
ine concentration was measured using an alkaline
picrate method (Olympus AU800 autoanalyser; interas-
say CV 2 %). For persons with urinary albumin below
the detectable limit, a pragmatic albumin value of
0.1 mg/L was used in the calculation of ACR.
As previously described [17, 19], for the subsequent
follow-up period (from baseline survey in 1995 to 31
December 2004 in two communities and 31 December
2005 in one community), follow-up of the participants’
records was accessed from hospital admissions (includ-
ing emergency presentations) and primary health care
(PHC) care providers to seek information including:
ACR; body-mass-index (BMI) and waist-hip-ratio
(WHR); smoking status; cardiovascular disease outcomes
(clinically diagnosed ischaemic heart disease, ischaemic
stroke or peripheral vascular disease (International clas-
sification of diseases, 10th revision [ICD-10] codes I20–
I25, I63–I69, I70– I89; or 9th revision [ICD-9] codes
410–414, 433–438, 440–459); diabetes (ICD-10 codes
E10–E15 or ICD-9 code 250, two or more blood glucose
readings >11.1 mmol/L, or two or more fasting blood
glucose readings >7.0 or prescription of hypoglycaemic
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medication); and hypertension (ICD-10 codes I10–I15 or
ICD-9 codes 401–405, three or more blood pressure
readings >140/90 mmHg, or prescription of antihyper-
tensive medication). Further information was collected
from death certificates, autopsy findings and the Na-
tional Death Index. Primary ESKD was considered on
the basis of clinical diagnosis in the participant’s medical
records (ICD-10 code N18.6 or ICD-9 code 585.6), an
indication of initiating renal replacement therapy or re-
quiring a kidney transplant. For the purpose of this ana-
lysis, dialysis for acute kidney failure was not included.
Renal mortality was defined as any primary or secondary
cause of death associated with renal failure (excluding
infections). CVD was considered present with the clin-
ical diagnosis of coronary heart disease (ischaemic heart
disease, acute myocardial infarction or angina pectoris
[excluding congenital or rheumatic heart diseases]),
stroke (ischaemic, haemorrhagic or unspecified), periph-
eral vascular disease or chronic heart failure indicated by
confirmed diagnoses in PHC records, relevant ICD
codes in hospital records or cause of death [17, 19]. Date
of first diagnosis of each condition was noted, along with
date of diagnosis of diabetes.
The present study is based on data from women and
men aged 15 years and over. We excluded participants
from the main cohort who were diagnosed with CVD (n
= 89) and/or CKD (n = 26) before baseline recruitment.
Thus, the number of the cohort participants included in
this set of analyses was 623 women and men.
Indirectly standardised for age and sex, incidence rates
(with 95 % confidence intervals; CIs) were calculated for
outcomes including ESKD, dialysis, CVD, renal mortal-
ity, chronic disease mortality (CVD, renal, cancer or dia-
betic cause of death) and all-cause mortality (including
and excluding trauma such as motor vehicle accidents)
among all participants and among participants who had
a normal (ACR <3.5 mg/mmol) or an abnormal ACR
measurement (ACR ≥3.5 mg/mmol). Gender-specific
ACR criteria for defining levels of albuminuria were not
applied due to the body composition characteristics for
this population [18], indeed gender specific cut-offs are
not incorporated in the guidelines developed by Kidney
Disease Improving Global Outcomes (KDIGO) [20]. A
non-diabetic subgroup from the three central Australian
communities was used as a reference population for in-
direct standardisation.
Cox’s proportional hazards models were used to es-
timate hazard ratios (HR) and 95 % CIs of ESKD, dia-
lysis, CVD, combined chronic disease mortality and
all-cause mortality associated with an abnormal base-
line albuminuria measurement. The small number of
participants (n = 51) and follow-up time (663 person-
years) did not allow for the estimation of a third cat-
egory of baseline ACR levels >35 mg/mmol. Person-
years were calculated from the time of recruitment
until incident diagnosis or end of follow-up period.
Multivariable models adjusted firstly for age, gender
and then community were assessed. An extended
multivariable model with further adjustment for po-
tential confounders was also assessed. Only statisti-
cally significant covariates (identified initially through
univariate analyses) were assessed using backwards se-
lection and retained in the model. Additional covari-
ates beyond age, gender and community that were
assessed included baseline categorical measures of
diabetes (yes/no), fasting glucose tertiles, BMI (WHO
categories), waist-to-hip ratio (0.90 >WHR < 0.90), ab-
stinence from alcohol (yes/no), current smoking (yes/
no), hypertension (SBP ≥140 mmHg and/or DBP
≥90 mmHg or current anti-hypertensive medication
including angiotensin-converting-enzyme inhibitor
(ACEi)] (yes/no), prevalent UTI (yes/no), haematuria
and homocysteine quartiles (μmol/L). Missing values
(generally <4 %) were accounted for by creating an
extra category in each covariate. A sensitivity analysis
was completed to assess the differing influence fasting
glucose and baseline diabetes had on the final model.
As a result baseline diabetes did not have a strong in-
fluence on the final model and was not used in the
final model (data not shown).
To assess clinical factors associated with an increase
in ACR into categories of moderately increased albu-
minuria (3.5-35 mg/mmol) and/or severely increased
albuminuria (ACR >35 mg/mmol), and therefore in-
creasing in the risk categories of the KHA Risk
Matrix, a subgroup of the cohort (n = 277) was cre-
ated among participants who had both a baseline
measurement of ACR of ≤35 mg/mmol and a follow-
up measurement of ACR in their medical records.
Due to the renoprotective association of ACEi and
ARBs with CKD we also excluded participants who
were taking anti-hypertensive medication (including
ACEi and ARBs) [21]. A new outcome event was cre-
ated to indicate a change in ACR levels that would
move the participant to a lower or higher risk cat-
egory on the KHA Risk Matrix (from green/normal
risk category [<3.5 mg/mmol] to yellow/mild risk cat-
egory [3.5-35 mg/mmol] or red/high risk category
[>35 mg/mmol]; or from yellow to red) according to
their follow-up ACR measurement. In this analysis,
only ACR was used as an indicator of kidney damage.
Kidney function (i.e. eGFR) was not used because
only 2 participants from the analytical subcohort had
a baseline eGFR assessment. We were therefore un-
able to incorporate the orange/moderate risk category
(<3.5 mg/mmol and an eGFR 30–44 mL/min/1.73 m2
or 3.5-35 mg/mmol and an eGFR of 30–60 mL/min/
1.73 m2) of the KHA Risk Matrix in this part of the
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analysis. Using the green/normal risk category in the
KHA Risk Matrix as the reference category, multi-
nomial logistic regression was used to calculate odds
ratios (ORs) and 95 % CIs of progression in the KHA
Risk Matrix to the yellow zone (3.5-35 mg/mmol) or
the red zone (>35 mg/mmol) associated with baseline
characteristics including UTI, hypertension, alcohol
consumption, current smoking, diabetes, BMI and
WHR. Only the multinomial logistic regression
models adjusted for baseline ACR, age, gender and
community are presented. Mutual adjustment for
baseline diabetes, WHR and hypertension was used to
assess whether these factors were independently asso-
ciated with risk. All statistical analyses were per-
formed using the SAS software package, version 9.4
(SAS Institute, Cary, NC).
Results
Risk associated with abnormal baseline albuminuria
A total of 623 people were followed for a total of 6009
person-years. Baseline characteristics of the participants
from the three central Australian communities accord-
ing to baseline ACR levels are shown in Table 1. Of the
participants who had a baseline ACR reading, 69.3 % (n
= 413) had normal ACR levels and 30.7 % (n = 180) of
participants had an ACR of ≥3.5 or higher levels. There
were a total of 30 participants who did not have a base-
line ACR measurement. These participants had similar
characteristics to the participants with an ACR ≥3.5 with
the exception that were fewer diabetics; had lower me-
dian BMI; less hypertension and fewer current smokers.
Among the 623 participants, a total of 16 incident
cases of ESKD were observed, of whom all but three
Table 1 Baseline characteristics for 623 central Australian cohort participants stratified by baseline ACR level
All participants ACR <3.5 mg/mmol ACR ≥3.5 mg/mmol
(n = 623) (n = 413) a (n = 180) a
Age at recruitment 30 (15–85) 28 (15–79) 35 (16–85)
Age at end of follow-up 40 (19–90) 38 (19–89) 45 (27–90)
Years of follow-up 9.8 (0.5-10.8) 9.8 (0.9-10.8) 9.8 (0.5-10.8)
Person-years of follow up 6009 4001 1734
Male gender 267 (42.9) 189 (45.8) 67 (37.2)
Diabetes at baseline 79 (12.7) 28 (6.8) 47 (26.1)
Fasting glucose, mmol/L 4.4 (2.7-19.8) 4.3 (2.7-17.2) 4.7 (3.2-19.8)
BMI, kg/mb 25.2 (13.4-51.1) 24.4 (13.4-48.4) 26.6 (15.5-51.1)
WHR 0.87 (0.70-1.33) 0.86 (0.70-1.33) 0.89 (0.73-1.20)
Alcohol abstinence 395 (62.3) 244 (40.26) 132 (66.3)
Current smoker 177 (29.2) 131 (32.3) 42 (24.1)
Hypertension 127 (20.4) 57 (13.8) 64 (35.6)
Systolic BP, mmHg 125 (93–198) 124 (95–174) 130 (93–198)
Diastolic BP, mmHg 72 (44–119) 70 (44–105) 75 (51–117)
ACEi use 1 (0.2) 1 (0.2) 0
Other BP medication use 13 (2.1) 6 (1.5) 6 (3.3)
Homocysteine, μmol/L 13.5 (4.0-46.1) 13.2 (4.0-46.1) 14.1 (5.9-41.2)
Prevalent UTI 42 (6.7) 26 (6.3) 15 (8.3)
Prevalent haematuria
Nil 442 (70.9) 303 (73.4) 111 (61.7)
Trace 70 (11.2) 48 (11.6) 22 (12.2)
Small 42 (6.7) 25 (6.1) 17 (9.4)
Moderate 30 (4.8) 21 (5.1) 8 (4.4)
Large 39 (6.3) 16 (3.9) 22 (12.2)
KHA Matrix Green Zoneb 201 (64.4) 201 (100.0) 0
KHA Matrix Yellow Zoneb 82 (26.3) 0 82 (73.9)
KHA Matrix Red Zoneb 29 (9.3) 0 29 (26.1)
aExcludes 30 participants without a baseline ACR measurement; bBased upon baseline ACR measurement among participants with 1 or more ACR measurements
during follow-up (n = 312). Continuous data are median (range), categorical data are prevalence and presented as n (%). BMI Body mass index, WHR Waist hip ratio,
ACEi Angiotensin-converting-enzyme inhibitor, ACR Albumin creatinine ratio, BP Blood pressure, UTI Urinary tract infection, KHA Kidney Health Australia
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were given dialysis (Table 2). The overall standardised
incidence rate (SIR) for ESKD was 340/100,000 person-
years, this being significantly higher among participants
with elevated baseline ACR levels. Likewise, SIRs for dia-
lysis, CVD, chronic disease mortality, all-cause mortality
(including and excluding traumatic deaths) were all sig-
nificantly higher among participants with elevated base-
line ACR. Of the four deaths attributed to renal failure,
three were among participants with abnormal baseline
albuminuria.
Cox’s proportional hazards models showed that an ele-
vated baseline ACR was associated with an almost 11-
fold risk of ESKD and a 17-fold risk of dialysis after ad-
justment for age and gender (Table 3; Model 1). Only a
borderline risk association of elevated ACR was ob-
served with CVD and no association was observed with
mortality from all-causes and chronic diseases. Control-
ling for BMI made little difference to the strength of the
association of an abnormal baseline ACR with ESKD
(HR = 11.5 [95 % CI 2.44-54.0], p-value = 0.003) and dia-
lysis (HR = 18.4 [95 % CI 2.28-148], p-value = 0.006).
Further adjustment for baseline WHR did not alter the
association with ESKD and dialysis (data not shown).
These effects were slightly attenuated with adjustment
for community of residence (Model 2). The final
model (Model 3) included the further adjustment of
blood pressure medication at baseline and fasting glu-
cose. Model 3 showed a slightly attenuated risk esti-
mate in comparison to Model 2; however, the
strength of the association of ESKD and dialysis with
ACR remained very strong.
Progression of albuminuria
A total of 277 participants had a baseline reading of
ACR <35 mg/mmol, at least one ACR follow-up screen-
ing and were not prescribed blood pressure medication.
Overall, this subpopulation was generally similar charac-
teristics to the overall analytical cohort with a slightly
higher prevalence of diabetes at baseline (Table 4). Par-
ticipants who were observed to have an increase in albu-
minuria were generally more likely to be female and had
a higher proportion of baseline diabetes and hyperten-
sion. The mean follow-up time from baseline recruit-
ment to follow-up ACR measurement for participants
who remained in the KHA green zone (normal risk cat-
egory) was 9.3 years, 8.7 years for participants that pro-
gressed to the KHA yellow zone (mildly increased risk
category) and 7.8 years for participants who progressed
to the KHA red zone (very high increased risk category).
Multinomial logistic regression models adjusted for
baseline ACR, age, gender and community showed that
baseline diabetes was associated with a more than two-
fold increased risk of progression to the yellow zone of
the KHA Risk Matrix and more than four-fold risk of
progression to the red zone (very high increased risk)
from the green zone (normal risk) (Fig. 1 and Additional
file 1: Table S1). Diabetes was independently associated
with risk of a strong increase in albuminuria even after
further adjustment for baseline hypertension and WHR
(from green to yellow OR = 2.51 [95 % CI 0.94-6.68], p-
value = 0.06; from green to red OR = 3.76 [95 % CI 1.17-
12.08], p-value = 0.03). Abdominal obesity was also asso-
ciated with a two-fold increased risk of progression of
Table 2 Standardised1 incidence rates for ESKD, dialysis, CVD and mortality
All participants ACR <3.5 mg/mmol d ACR ≥3.5 mg/mmol d
Outcome Events Person-
yearsb
Incidencec
(95%CI)
Events Person-
yearsb
Incidencec
(95%CI)
Events Person-
yearsb
Incidence
(95%CI)
Diagnosis
ESKD 16 5,961 340 (334–346) 2 4,001 70 (67–73) 12 1,691 789 (774–809)
Dialysis 13 5,976 212 (202–222) 1 4,000 26 (22–31) 10 1,706 512 (484–539)
CVD 67 5,769 1,060 (1037–
1083)
33 3,909 868 (841–895) 31 1,604 1437 (1391–
1483)
Mortality
Renal death 4 6,009 61 (60–62) 0 4,001 - 3 1,734 125 (122–128)
All chronic disease deaths
combinede
19 6,009 283 (276–290) 8 4,001 203 (196–211) 9 1,734 364 (351–377)
Non-traumatic deathf 40 6,009 617 (603–631) 17 4,002 446 (430–461) 17 1,734 746 (721–772)
All-cause mortality 53 6,009 860 (839–880) 28 4,002 730 (707–754) 18 1,734 904 (867–941)
aThe standard population used is the non-diabetic cohort members; bperson-years = time from recruitment until incident diagnosis or end of follow up period and
rounded to nearest full number; cper 100,000 person-years, showing age and gender adjusted standardised incidence rate; dexcludes 30 participants without a
baseline ACR measurement; eCVD, renal, cancer or diabetic cause of death; fexcluding a traumatic cause of death. NB: A total of 53 participants died during the
follow-up period (all-cause mortality), of which 40 were considered non-traumatic deaths (that is, not including deaths such as motor vehicle accidents and homi-
cides). Of the non-traumatic deaths, any underlying cause of death attributed to a chronic disease, including CVD, renal disease, cancer or diabetes was considered
a chronic disease death (n = 19). Of the chronic disease attributed deaths, four had renal underlying causes recorded. The difference between the numbers of all
participants and the ACR categories is due to the 30 participants without a baseline ACR measurement. ESKD End stage kidney disease, CVD Cardiovascular dis-
ease, ACR Albumin creatinine ratio
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ACR levels between 3.5-35 mg/mmol and almost four-
fold risk of progression of ACR levels >35 mg/mmol.
Further adjustment for baseline diabetes, baseline ACR
levels and hypertension only slightly attenuated the asso-
ciation with WHR (from green to yellow OR = 2.13
[95 % CI 1.12-4.04], p-value = 0.02; from green to red
OR = 3.26 [95 % CI 1.36-7.82], p-value = 0.008). Smok-
ing, baseline UTI, or hypertension were not significantly
associated with progression in the KHA Risk Matrix. A
BMI >25 kg/m2 was generally associated with a signifi-
cantly increased odds of progression in the KHA Risk
Matrix. Alcohol consumption was associated with a
moderate progression in ACR level, however alcohol
consumption was not associated with follow-up ACR
levels greater than 35 mg/mmol. Further adjustment
for the respective models that included hypertension
(both diastolic and systolic), UTI, haematuria, homo-
cysteine, smoking, and alcohol consumption was not
informative and did not substantially change the re-
sults (data not shown).
Discussion
In this central Australian Aboriginal community-based
cohort, a single abnormal albuminuria reading was
Table 3 Hazard ratio associated with ACR ≥3.51 for ESKD, dialysis, CVD and mortality
Model 1b Model 2 c Model 3 d
Outcome Events HR 95 % CI P-value HR 95 % CI P-value HR 95 % CI P-value
Clinical Diagnosis
ESKD 12 10.7 (2.31-49.1) 0.002 9.55 (2.08-43.9) 0.004 7.60 (1.42-40.6) 0.018
Dialysis 10 17.4 (2.16-139) 0.007 15.2 (1.89-121) 0.010 13.0 (1.41-119) 0.024
CVD 31 1.79 (1.08-2.97) 0.024 1.66 (1.00-2.75) 0.052 1.23 (0.71-2.13) 0.462
Mortality
All chronic disease attributed deaths combinede 9 2.00 (0.72-5.52) 0.182 1.99 (0.71-5.53) 0.189 2.39 (0.76-7.49) 0.136
Non-traumaticf 17 1.59 (0.77-3.29) 0.215 1.53 (0.73-3.19) 0.262 1.94 (0.85-4.42) 0.117
All-cause mortality 18 1.12 (0.58-2.15) 0.739 1.11 (0.57-2.16) 0.751 1.40 (0.68-2.90) 0.365
aACR < 3.5 mg/mmol as reference category and excludes 31 participants without an ACR measurement at baseline recruitment; bModel 1 adjusted for gender and
age at baseline recruitment; cModel 2 adjusted for gender, age at baseline recruitment and community; dModel 3 adjusted for gender, age at baseline
recruitment, community, and further adjusted for baseline blood pressure medication and fasting glucose at baseline; eAny underlying cause of death attributed
to a chronic disease, including CVD, renal disease, cancer or diabetes; fAll deaths excluding a traumatic cause of death (such as a motor vehicle accidents). ESKD
End stage kidney disease, CVD Cardiovascular disease, ACR Albumin creatinine ratio
Table 4 – Characteristicsa of 277 participants with a baseline reading of ACR ≤35 mg/mmol2 by follow-up ACRc
All
participants
Green/normal risk category (ACR
<3.5)
Yellow/mild risk category (ACR 3.5-
35)
Red/high risk category (ACR
>35)
(n = 277) (n = 139) (n = 93) (n = 45)
Age at recruitment 31 (15–74) 29 (16–70) 33 (15–70) 30 (16–74)
Age at exit 40 (19–80) 40 (19–75) 41 (22–80) 40 (23–80)
Male gender 127 (45.9) 66 (47.5) 45 (48.4) 16 (35.6)
Alcohol abstinence 166 (61.3) 88 (63.8) 48 (53.3) 30 (69.8)
Current smoker 78 (28.9) 39 (28.3) 28 (31.5) 11 (25.6)
Diabetes 42 (15.2) 9 (6.5) 18 (19.4) 12 (33.3)
BMI, kg/mb 25.8 (14.6-
48.4)
24.8 (14.6-44.1) 26.4 (16.7-46.2) 26.9 (19.6-48.4)
WHR 0.87 (0.70-
1.33)
0.85 (0.70-1.04) 0.89 (0.70-1.33) 0.91 (0.78-1.03)
Hypertension 53 (19.1) 25 (18.0) 17 (18.3) 11 (24.4)
Systolic BP, mmHg 125 (93–184) 124 (93–134) 125 (96–184) 127 (103–164)
Diastolic BP,
mmHg
71 (44–108) 71 (45–108) 70 (44–105) 72 (53–100)
Homocysteine, μM 13.8 (4.0-46.1) 13.2 (6.3-46.1) 14.6 (7.0-37.9) 12.4 (3.4-41.1)
Prevalent UTI 14 (5.1) 7 (5.0) 4 (4.3) 3 (6.7)
aContinuous data are median (range), categorical data are prevalence, presented as n (%);b with at least one ACR measurement during follow-up and were not
users of blood pressure medication (including ACEi); c according to KHA Risk Matrix zones – green/normal risk category, yellow/mildly increased risk category and
red/very high increased risk category. BMI Body mass index, WHR Waist hip ratio, ACR Albumin creatinine ratio, BP Blood pressure, UTI Urinary tract infection
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independently associated with a strongly increased risk
of ESKD, dialysis and possibly CVD outcomes over the
subsequent 10 years. Given the high burden of CKD in
remote Aboriginal communities and the strong risk as-
sociation of a single abnormal ACR level with future
ESKD and dialysis outcomes, these results warrant an
appropriate clinical response to an abnormal spot ACR
assessment. Diabetes and a WHR ≥0.90 were both inde-
pendently associated with risk of progression in ACR
levels, suggesting that including abdominal adiposity as
an early target for CKD prevention strategies may merit
investigation. We have therefore identified clinical pre-
dictors of a significant progression in ACR levels that
can also be readily measured in remote Australian PHC
settings.
An abnormal albuminuria level (i.e. an ACR of ≥3.5 or
higher) has been consistently reported to be associated
with subsequent renal disease, CVD and natural death
[22] in other populations [23–26] including the Tiwi
community [3, 5]. Therefore the association of a single
baseline reading predicting ESKD and dialysis outcomes
is not new. However, the strength of the association is
striking even after controlling for baseline UTI, diabetes
and obesity. CKD and ESKD are thought to be caused
by persistent low birth weights (low number of nephrons
[8]), maternal and infant malnutrition, repeated and per-
sistent infections and inflammation that damage the
kidneys, and changes to the exercise and dietary patterns
related to “Westernization” [5, 8]. Other factors that
contribute to the excess kidney disease levels in this
group are a high prevalence of diabetes, smoking and
poor diet and inadequate access to basic health hard-
ware, a healthy food supply and other preventive services
[5, 8]. The current data support the clinical guidelines
developed specifically for this population group in terms
of renal disease screening approaches including the use
of the KHA Risk Matrix [15]. To our knowledge, this is
the first time the ACR component of the KHA Risk
Matrix has been used to evaluate CKD risk among Abo-
riginal people in a remote setting.
Within this population who live with the burden of a
high incidence of ESKD, CVD and mortality, in terms of
interventions, a spot check for an ACR measurement of
≥3.5 mg/mmol is a potentially cost effective method ap-
plicable to the remote setting. It presents itself as a can-
didate able to assess future risk of ESKD and CVD
which could lead to better directed prevention strategies
being initiated at a stage earlier in the disease process.
While current guidelines for CKD diagnosis involve two
eGFR or ACR readings at least three months apart, a
single ACR measurement, as recommended elsewhere
[11, 15], may be an effective surrogate. We propose not
a tool for diagnosing CKD but a tool to screen, within a
population at high risk, people who could benefit from
Fig. 1 Baseline predictors of progression in the KHA Risk Matrix Legend: The odds of progression to yellow (3.5 – 35 mg/mmol) and to red
(>35 mg/mmol) as described in the Kidney Health Australia, clinical guidelines [7] and the Central Australian Rural Practitioners Association
(CARPA) Standard Treatment guidelines [11]. All models adjusted for age, gender, community and ACR at baseline. *Pvalue <0.05; **Pvalue≤ 0.01.
95 % Confidence intervals and Pvalues are shown in Additional file 1: Table S1
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earlier CKD prevention strategies. The present results
strongly support the use of a single ACR reading, as it is
already within the annual Medicare adult health check
for Aboriginal and Torres Strait Islander people. Using a
single ACR of ≥3.5 mg/mmol as a means to identify
people at risk of ESKD may result in a possible excess in
the clinical classification of at-risk due to the association
of prevalent UTI and ACR. However, we propose that
the inclusion of people over-classified as ‘at risk’ would
be preferable than the current under classification and
under diagnosis of CKD in remote communities.
Surprisingly, we observed no association between
hypertension and progression within the KHA Risk
Matrix which is counter to established risk factors for
ESKD [27]. Within this statistical model we controlled
for the use of baseline hypertensive medication by ex-
cluding participants using baseline hypertensive medica-
tion from the model and the median systolic and
diastolic blood pressure were within normal ranges. We
were unable to disentangle the relationship between
blood pressure and ACR; specifically whether an in-
crease in ACR precedes hypertension or vice versa. It is
possible that albuminuria and hypertension share a com-
mon and parallel aetiology, with both conditions reflect-
ing vascular damage from inflammatory processes
secondary to oxidative stress of the endothelium and
sub-endothelial tissues [19]. The lack of an association
of hypertension and progression within the KHA Risk
Matrix may also be a chance finding.
With the number of prevalent cases of Aboriginal
and Torres Strait Islander People with treated end-
stage kidney disease increasing [28] along with ad-
vances to treatment and sustainment of life, the un-
sustainable cost of renal failure is not only a health
service provision and health care costing issue, but
also the loss of community members who opt out of
receiving treatment and premature death and/or re-
locating to larger towns for renal replacement ther-
apy. Interventions to reduce the risk of CKD will only
be sustainable if they are applied over the life-course
and address underlying socio-economic conditions
and social determinants of health [4]. Targeted inter-
ventions include improving the health of women be-
fore and during pregnancy with nutrition and spacing
of births, reducing smoke and alcohol exposure in
utero and management of diabetes in pregnancy,
avoiding under nutrition and preventing obesity in in-
fancy and childhood and ensuring adequate public
health measures to avoid repeated infections [4]. Fur-
thermore, the monitoring of albuminuria and treating
hypertension with renoprotective therapy along with
aggressive management of diabetes have been shown
to reduce renal failure, cardiovascular disease and
mortality in a Australian Aboriginal community [29,
30]. ACR is amenable to point of care testing in the
remote primary health care setting [9]. Although eco-
nomic evaluation was outside the scope of this study,
others have found the screening cost incurred by re-
ducing the number of people with CKD progressing
into the high-cost treatment of ESKD would be a
more sustainable solution [10].
There are limitations to the current analysis and
its findings reported here. Our observations are from
central Australia and further investigation is required
to assess the applicability to other Aboriginal and
Torres Strait Islander populations particularly given
the variability of other characteristics such as envir-
onment and socioeconomic factors affecting risk pro-
files [31]. However, as an intermediate indicator
between environmental drivers of risk and ESKD, a
spot ACR is a potentially generalizable screening
tool. Furthermore this study adds to a growing evi-
dence base among Aboriginal and Torres Strait Is-
lander populations for the role of albuminuria
>3.5 mg/mmol as a marker of early CKD [3, 5]. We
were unable to expand the combined CVD endpoint
according to PVD, stroke, CHD and CHF outcomes.
This may explain the borderline significance of CVD.
However, in a recent study an ACR cut off of ≥
5.7 mg/mmol was associated with more than a 2-
fold increased odds of CVD [17], so the current cut
off of ≥ 3.5 mg/mmol used in this analysis may have
been too low to capture the CVD risk association.
Further, we understand that these diseases do not
necessarily have the same aetiology and may be asso-
ciated with ACR differently. In addition, among earl-
ier cases of ESKD and CVD, ICD-9 codes were used
for the diagnosis of renal and CVD outcomes. This
may have led to an under-diagnosis and could have
biased the results towards the null. Previous studies
have reported substantial intra-individual variability
of ACR [32] from day-to-day spot urine samples and
this could be a source of error. However, given the
strong association with ESKD and baseline ACR in
this population, a single spot check as a diagnostic
tool warrants further investigation, and has been
shown to be robust measure of renal disease [10] in-
cluding among remote Aboriginal populations [3].
This analysis was not a screening and diagnostic
study therefore sensitivity and specificity were not
examined. Furthermore, participants with ACR mea-
surements during their follow-up tended to be less
healthy than participants who only had an ACR at
baseline measurement. The use of eGFR as per the
screening protocol as recommended by KHA also re-
quires investigation, because ACR and eGFR are not
always associated in the same way as in non-
Indigenous Australians: in an urban setting a high
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prevalence of microalbuminuria but not low eGFR
was observed in an Indigenous population [33].
Conclusions
Baseline albuminuria was a strong predictor of risks
of ESKD and dialysis in this population. For clinical
identification of individuals at risk of future ESKD, a
single spot urine ACR analysis may be a useful and
efficient strategy to screen for future CKD risk among
remote communities. Targeting individuals with dia-
betes and high central obesity to avoid increases in
albuminuria may also prevent future CKD and CVD
complications. This research provides evidence that
the KHA Risk Matrix classification applied in the
PHC setting is useful in identifying Aboriginal per-
sons at elevated risk of CKD.
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